Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Nrgene (NRGN) Stock Price & Analysis

0 Followers

NRGN Stock Chart & Stats

ILA 65.00-ILA 4.30(-6.20%)
At close:
ILA 100ILA 150Aug 10Aug 24Sep 8Sep 22Oct 5Oct 19Nov 5
Day’s Range
ILA 65.00 - ILA 65.00
52-Week Range
ILA 65.00 - ILA 305.90
Previous Close
ILA 69.30
Volume
N/A
Average Volume (3M)
5,975
Market Cap
ILS 9.24M
Enterprise Value
ILS 5.76T
Total Cash (Recent Filing)
ILS 3.18M
Total Debt (Recent Filing)
ILS 145.02K
Price to Earnings (P/E)
―
Beta
0.62
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Margin Rebound

The sharp 2025 revenue recovery and materially higher gross margin indicate improved commercial traction and stronger unit economics. If sustained, these gains could provide a better foundation for scaling the software platform and moving the company toward profitability over coming quarters.

Conservative Leverage

Very low debt relative to equity reduces interest and refinancing pressure, preserving financial flexibility while the company develops its genomics software business. This balance-sheet position can support continued investment and gives management more room to navigate operating volatility.

Improved Operating Cash Flow

The return to positive operating cash flow is an important improvement in the company’s ability to fund operations internally. Although the scale remains limited, better cash generation reduces dependence on external financing and supports the durability of the 2025 operating recovery.

Bears Say

Persistent Operating Losses

The company has not yet converted revenue growth and improved gross margin into sustainable operating earnings. Deeply negative EBIT and net margins weaken internal funding capacity, constrain strategic flexibility, and leave future performance dependent on further improvement in scale and cost absorption.

Unproven Free Cash Flow

Free cash flow is only slightly positive and has been volatile after several years of heavy cash burn. This limited conversion of operations into cash means the recent rebound has not yet demonstrated durable financial self-funding or a reliable buffer for investment and business setbacks.

Equity And Shareholder-return Pressure

Negative returns to shareholders show that the current business remains economically inefficient despite its recent revenue recovery. The prior period of negative equity also highlights how continued losses can weaken the capital base over time and reduce resilience if profitability does not improve.

NRGN FAQ

What was Nrgene’s price range in the past 12 months?
Nrgene lowest stock price was ILA 65.00 and its highest was ILA 305.90 in the past 12 months.
What is Nrgene’s market cap?
Nrgene’s market cap is ₪9.24M.
When is Nrgene’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nrgene’s earnings last quarter?
Nrgene released its earnings results on Mar 31, 2026. The company reported ILA 8.8 earnings per share for the quarter.
Is Nrgene overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Nrgene pay dividends?
Nrgene does not currently pay dividends.
What is Nrgene’s EPS estimate?
Nrgene’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nrgene have?
Nrgene has 13,327,785 shares outstanding.
What happened to Nrgene’s price movement after its last earnings report?
Nrgene reported an EPS of ILA 8.8 in its last earnings report. Following the earnings report the stock price went down -3.988%.
Which hedge fund is a major shareholder of Nrgene?
Currently, no hedge funds are holding shares in IL:NRGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology